Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Cardiovascular disease is the leading cause of death globally1 HLS New Drug Submission (NDS) for Vascepa is supported by data from the REDUCE-IT™ trial, an international, multi-center...
Revenue of $61.4 million, Adjusted EBITDA of $41.1 million and Cash from Operations of $32.7 million for the year-ended December 31, 2018 REDUCE-IT™ cardiovascular outcomes study of Vascepa®,...
Approximately 159 Fewer Major Adverse Cardiovascular Events per 1000 Patients Studied Data Show Relative Benefits of Vascepa Usage Grow Over Time TORONTO, March 19, 2019 /CNW/ - HLS Therapeutics...
HLS Therapeutics Inc. ("HLS" or the "Company") (TSX:HLS), a specialty pharmaceutical company focused on central nervous system and cardiovascular markets, announces that on March 16, 2019, Amarin...
From a single drop of blood from the tip of a finger, the point-of-care technology generates white blood cell counts and neutrophils numbers in minutes When approved in Canada, the Athelas One...